Somatostatin Analogs Market Analysis

Type (Octreotide, Lanreotide, Pasireotide)

The octreotide segment is estimated to hold 44% share of the global somatostatin analogs market in the coming years owing to the rising prevalence of neuroendocrine tumors. Neuroendocrine tumors, also known as neuroendocrine tumors (NET), are a rare type of tumor that begins in specialized cells called neuroendocrine cells that most usually occur in the intestine, where they are known as carcinoid tumors. Moreover, they arise when neuroendocrine cells' DNA changes and forms in cells that interact with the neurological system or in glands that generate hormones. 

Octreotide also known as Sandostatin is licensed for the treatment of clinical syndromes and tumor growth as it is a synthetic version of the natural hormone somatostatin used to control the growth of some advanced neuroendocrine tumors (NETs) when surgery is not an option to considerably enhance the neuroendocrine tumors treatment. According to estimates, each year, over 11, 000 persons in the United States are diagnosed with neuroendocrine tumors (NET).

Additionally, the pasireotide segment is anticipated to gain a notable share by the year 2036. Pasireotide is a man-made protein that functions similarly to the hormone somatostatin in the body and is used to treat Cushing's disease, an abnormal condition caused by excess hormones in patients for whom pituitary surgery is not an option. Pasireotide is marketed under the brand names Signifor a quick-acting variant that is injected under the skin twice a day and Signifor LAR a long-acting variant that is injected into the buttock muscle by a healthcare provider every month.

Application (Acromegaly, Neuroendocrine Tumors)

The acromegaly segment in the somatostatin analogs market is set to garner a notable share shortly. Acromegaly is a rare disorder in which the body creates excessive amounts of growth hormone and is typically diagnosed in individuals aged 30 to 50, but it can afflict persons of any age. Moreover, it is an uncommon but deadly medical illness caused by an overproduction of growth hormone by the pituitary gland during maturity. 

Drug therapy, including somatostatin analogs (SAs), dopamine receptor agonists, and growth hormone receptor antagonists (pegvisomant, PEG), is routinely used to treat individuals with acromegaly who do not respond to surgery.

Our in-depth analysis of the global market includes the following segments: